Calcitonin Gene-Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine

New England Journal of Medicine

Volumn 350, Issue 11, 2004, Pages 1104-1110

  Olesen, Jes ^a   Diener, Hans Christoph ^b   Husstedt, Ingo W ^c   Goadsby, Peter J ^d   Hall, David ^e   Meier, Ulrich ^f   Pollentier, Stephane ^f   Lesko, Lynna M ^e  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^f BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMIGRAINE AGENT; BIBN 4096 BS; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; OLCEGEPANT; PIPERIDINE DERIVATIVE; PLACEBO; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ACUTE DISEASE; ADULT; ANALGESIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA; PAIN ASSESSMENT; PARESTHESIA; PHOTOPHOBIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TIME; TREATMENT OUTCOME; VISUAL DISORDER; XEROSTOMIA;

EID: 1542346238     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa030505     Document Type: Article

References (36)

1. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41:646-57.
2. Rasmussen BK, Olesen J. Symptomatic and nonsymptomatic headaches in a general population. Neurology 1992;42:1225-31.
3. Menken M, Munsat TL, Toole JF. The Global Burden of Disease Study: implications for neurology. Arch Neurol 2000;57:418-20.
4. Goadsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment. N Engl J Med 2002;346:257-70.
5. Edvinsson L, Krause DN, eds. Cerebral blood flow and metabolism. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2002.
6. Jansen-Olesen I, Mortensen A, Edvinsson L. Calcitonin gene-related peptide is released from capsaicin-sensitive nerve fibres and induces vasodilatation of human cerebral arteries concomitant with activation of adenylyl cyclase. Cephalalgia 1996;16:310-6.
7. Williamson DJ, Hargreaves RJ, Hill RG, Shepheard SL. Intravital microscope studies on the effects of neurokinin agonists and calcitonin gene-related peptide on dural blood vessel diameter in the anaesthetized rat. Cephalalgia 1997;17:518-24.
8. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990;28:183-7.
9. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia 2002;22:54-61.
10. Doods H, Hallermayer G, Wu D, et al. Pharmacological profile of BIBN4096BS, the first selective small molecular CGRP antagonist. Br J Pharmacol 2000;129:420-3.
11. Moreno MJ, Abounader R, Hebert E, Doods H, Hamel E. Efficacy of the non-peptide CGRP receptor antagonist BIBN4096BS in blocking CGRP-induced dilations in human and bovine cerebral arteries: potential implications in acute migraine treatment. Neuropharmacology 2002;42:568-76.
12. Headache Classification Subcommittee of the International Headache Society. The international Classification of Headache Disorders (second edition). Cephalalgia 2004; 24:Suppl 1:1-160.
13. Jennison C, Turnbull BW. Group sequential methods with applications to clinical trials. Boca Raton, Fla.: Chapman & Hall/CRC, 2000.
14. Moller S. An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses. Stat Med 1995;14:911-22.
15. Roon KI, Olesen J, Diener HC, et al. No acute antimigraine efficacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: results of two randomized, double-blind, placebo-controlled clinical trials. Ann Neurol 2000;47:238-41.
16. Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001;344:1594-602. [Erratum, N Engl J Med 2001;345:304.]
17. Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001;344:1594-602. [Erratum, N Engl J Med 2001;345:304.]
18. Tfelt-Hansen P, Block G, Dahlof C, et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000; 20:765-86.
19. Bendtsen L, Mattsson P, Zwart JA, Lipton RB. Placebo response in clinical randomized trials of analgesics in migraine. Cephalalgia 2003;23:487-90.
20. Jansen I, Uddman R, Ekman R, Olesen J, Ottosson A, Edvinsson L. Distribution and effects of neuropeptide Y, vasoactive intestinal peptide, substance P, and calcitonin gene-related peptide in human middle meningeal arteries: comparison with cerebral and temporal arteries. Peptides 1992;13:527-36.
21. Uddman R, Edvinsson L, Ekman R, Kingman T, McCulloch J. Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. Neurosci Lett 1985;62:131-6.
22. Jansen I, Uddman R, Hocherman M, et al. Localization and effects of neuropeptide Y, vasoactive intestinal polypeptide, substance P, and calcitonin gene-related peptide in human temporal arteries. Ann Neurol 1986;20:496-501.
23. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of human and the cat during activation of the trigeminovascular system. Ann Neurol 1988;23:193-6.
24. Zagami AS, Goadsby PJ, Edvinsson L. Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides. Neuropeptides 1990;16:69-75.
25. Buzzi MG, Carter WB, Shimizu T, Heath H III, Moskowitz MA. Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology 1991;30:1193-200.
26. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993;33:48-56.
27. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991; 325:316-21.
28. Goadsby PJ. The pharmacology of headache. Prog Neurobiol 2000;62:509-25.
29. Williamson DJ, Hargreaves RJ, Hill RG, Shepheard SL. Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat-intravital microscope studies. Cephalalgia 1997;17:525-31.
30. Akerman S, Williamson DJ, Kaube H, Goadsby PJ. Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. Br J Pharmacol 2002; 137:62-8.
31. Storer RJ, Akerman S, Goadsby PJ. Blockade of calcitonin gene-related peptide (CGRP) receptors in the trigeminocervical complex reduces trigeminovascular nociceptive traffic. Cephalalgia 2003;23:726. abstract
32. 1B/1D agonists inhibits trigeminal cell firing in the cat. Brain 1997;120:2171-7.
33. Iovino, M, Feifel U, Yong C-L, Wolters J-M, Wallenstein G. Safety, tolerability, and pharmacokinetics of BIBN 4096 BS, the first selective small molecular calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers. Cephalalgia (in press).
34. Petersen KA, Lassen LH, Birk S, Olesen J. The effect of the nonpeptide CGRP-antagonist, BIBN4096BS on human-alphaCGRP induced headache and hemodynamics in healthy volunteers. Cephalalgia 2003;23:725. abstract.
35. Petersen KA, Birk S, Lassen LH, Kruuse C, Jonassen O, Olesen J. The novel CGRP-antagonist, BIBN4096BS does not affect the cerebral hemodynamics in healthy volunteers. Cephalalgia. 2003;23:729. abstract.
36. 1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001;358:1668-75.